HRP20210068T1 - Opioidne formulacije - Google Patents

Opioidne formulacije Download PDF

Info

Publication number
HRP20210068T1
HRP20210068T1 HRP20210068TT HRP20210068T HRP20210068T1 HR P20210068 T1 HRP20210068 T1 HR P20210068T1 HR P20210068T T HRP20210068T T HR P20210068TT HR P20210068 T HRP20210068 T HR P20210068T HR P20210068 T1 HRP20210068 T1 HR P20210068T1
Authority
HR
Croatia
Prior art keywords
formulation
buprenorphine
depot
precursor
mass
Prior art date
Application number
HRP20210068TT
Other languages
English (en)
Croatian (hr)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210068(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Priority claimed from PCT/EP2013/065855 external-priority patent/WO2014016428A1/en
Publication of HRP20210068T1 publication Critical patent/HRP20210068T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
HRP20210068TT 2012-07-26 2013-07-26 Opioidne formulacije HRP20210068T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28
PCT/EP2013/065855 WO2014016428A1 (en) 2012-07-26 2013-07-26 Opioid formulations
EP13744494.9A EP2877155B1 (en) 2012-07-26 2013-07-26 Opioid formulations

Publications (1)

Publication Number Publication Date
HRP20210068T1 true HRP20210068T1 (hr) 2021-03-05

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210068TT HRP20210068T1 (hr) 2012-07-26 2013-07-26 Opioidne formulacije

Country Status (20)

Country Link
US (4) US12161640B2 (enExample)
JP (1) JP6417327B2 (enExample)
CN (1) CN109010255B (enExample)
AU (3) AU2016244271B2 (enExample)
CL (1) CL2015000197A1 (enExample)
CY (1) CY1124016T1 (enExample)
DK (1) DK2877155T3 (enExample)
EA (1) EA034855B1 (enExample)
ES (1) ES2837803T3 (enExample)
HK (1) HK1221636A1 (enExample)
HR (1) HRP20210068T1 (enExample)
HU (1) HUE053273T2 (enExample)
IL (3) IL296882A (enExample)
LT (1) LT2877155T (enExample)
MX (2) MX387722B (enExample)
MY (1) MY189481A (enExample)
NZ (2) NZ735248A (enExample)
PE (1) PE20150672A1 (enExample)
PT (1) PT2877155T (enExample)
SG (2) SG10201703964TA (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3691618A1 (en) * 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
EP4294367A4 (en) * 2021-02-18 2025-02-12 Navin Saxena Research and Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
WO2023020608A1 (zh) * 2021-08-20 2023-02-23 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ES2127835T3 (es) 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
AU685262B2 (en) 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
DE19536246A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP0871489A1 (en) 1995-10-12 1998-10-21 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
WO2002087543A1 (en) 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA05010821A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
PL1682091T3 (pl) 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
PL1845942T3 (pl) 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
US8097239B2 (en) 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
WO2010065930A1 (en) 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
US9168251B2 (en) 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
BR112013030104A8 (pt) 2011-05-25 2021-09-08 Camurus Ab Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit
US9555118B2 (en) 2011-12-05 2017-01-31 Camrus Ab Robust controlled-release peptide formulations
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US9592227B2 (en) 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
CN108348881A (zh) 2015-10-28 2018-07-31 托普索公司 乙苯脱氢成苯乙烯
WO2020077235A1 (en) 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression

Also Published As

Publication number Publication date
US20240131021A1 (en) 2024-04-25
CN109010255A (zh) 2018-12-18
NZ704012A (en) 2017-09-29
US20260097031A1 (en) 2026-04-09
MX387722B (es) 2025-03-18
PE20150672A1 (es) 2015-05-21
CL2015000197A1 (es) 2015-11-13
US20250049783A1 (en) 2025-02-13
AU2016244271B2 (en) 2018-01-18
HUE053273T2 (hu) 2021-06-28
AU2019200982A1 (en) 2019-02-28
CN109010255B (zh) 2022-10-21
ES2837803T3 (es) 2021-07-01
JP2015522649A (ja) 2015-08-06
CY1124016T1 (el) 2022-05-27
US12318379B2 (en) 2025-06-03
AU2017279657A1 (en) 2018-01-18
EA201590202A1 (ru) 2015-07-30
IL236762A0 (en) 2015-03-31
MX361873B (es) 2018-12-18
MY189481A (en) 2022-02-16
IL289157A (en) 2022-02-01
MX2015001033A (es) 2015-04-09
NZ735248A (en) 2018-10-26
DK2877155T3 (da) 2021-01-18
EA034855B1 (ru) 2020-03-30
LT2877155T (lt) 2021-02-25
AU2019200982B2 (en) 2019-07-18
JP6417327B2 (ja) 2018-11-07
AU2017279657B2 (en) 2018-11-15
PT2877155T (pt) 2020-12-18
SG10201703964TA (en) 2017-06-29
US20240226091A9 (en) 2024-07-11
HK1221636A1 (en) 2017-06-09
IL296882A (en) 2022-12-01
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
BR112015001548A2 (pt) 2017-07-04
AU2016244271A1 (en) 2016-10-27
US12161640B2 (en) 2024-12-10
HK1205948A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
IL251413B1 (en) Composition of injectable buprenorphine
JP2015522649A5 (enExample)
MX352024B (es) Formulaciones potentes de liberacion controlada.
WO2018045276A8 (en) Fused bicyclic sgc stimulators
PH12020550956A1 (en) Sgc stimulators
MX2013013401A (es) Formulaciones pepticidas de liberacion controlada.
MY193514A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
NZ597645A (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
RU2018119295A (ru) Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
PE20080765A1 (es) Formas de dosificacion farmaceutica
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
MX383392B (es) Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
PH12019501016A1 (en) Treatment of cns diseases with sgc stimulators
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
BR112012023974A2 (pt) composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HRP20200472T1 (hr) Liječenje alopecije areate
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
HRP20200432T1 (hr) Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva
EA201001507A1 (ru) Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
NZ730521B2 (en) Injectable buprenorphine formulation
MX393800B (es) L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.
MX2011011237A (es) Composiciones en capsulas de gelatina blanda masticables con enmascaradores de sabor.